Novavax Says U.S. Will Pause Funding for Production of Its Vaccine
The Maryland company, which has a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said it needed to address the concerns of federal regulators.
View original article
Contributor: Sharon LaFraniere
